Literature DB >> 23735907

The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits.

Eli D Ehrenpreis1, Parakkal Deepak, Humberto Sifuentes, Radha Devi, Hongyan Du, Jerrold B Leikin.   

Abstract

OBJECTIVES: We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events.
METHODS: Medical records of gastroparesis patients were evaluated for physician management choices. The FDA Adverse Event Reporting System (FAERS) was analyzed for event reports, and for lawyer-initiated reports, with metoclopramide from 2004 to 2010. Google Scholar was searched for court opinions against metoclopramide manufacturers.
RESULTS: Before the black box warning, 69.8% of patients received metoclopramide for gastroparesis, compared with 23.7% after the warning. Gastroenterologists prescribed domperidone more often after than before the warning. Metoclopramide prescriptions decreased after 2008. Adverse event reporting increased after the warning. Only 3.6% of all FAERS reports but 70% of TD reports were filed by lawyers, suggesting a distortion in signal. Forty-seven legal opinions were identified, 33 from 2009-2010.
CONCLUSIONS: The black box warning for metoclopramide has decreased its usage and increased its rate of adverse event reporting. Lawyer-initiated reports of TD hinder pharmacovigilance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23735907     DOI: 10.1038/ajg.2012.300

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   12.045


  27 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  National Trends in Treatment Initiation for Nursing Home Residents With Diabetes Mellitus, 2008 to 2010.

Authors:  Andrew R Zullo; David D Dore; Lori Daiello; Rosa R Baier; Roee Gutman; David R Gifford; Robert J Smith
Journal:  J Am Med Dir Assoc       Date:  2016-03-24       Impact factor: 4.669

Review 3.  Endoscopic botox injections in therapy of refractory gastroparesis.

Authors:  Andrew Ukleja; Kanwarpreet Tandon; Kinchit Shah; Alicia Alvarez
Journal:  World J Gastrointest Endosc       Date:  2015-07-10

4.  Time trends in gastroparesis treatment.

Authors:  Anwar Dudekula; Shiraz Rahim; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2014-09-26       Impact factor: 3.199

5.  Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.

Authors:  James R Rogers; Ameet Sarpatwari; Rishi J Desai; Justin M Bohn; Nazleen F Khan; Aaron S Kesselheim; Michael A Fischer; Joshua J Gagne; John G Connolly
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

Review 6.  In Search of the Ideal Promotility Agent: Optimal Use of Currently Available Promotility Agents for Nutrition Therapy of the Critically Ill Patient.

Authors:  Sarah J Diamond; Endashaw Omer; Laszlo Kiraly
Journal:  Curr Gastroenterol Rep       Date:  2017-11-16

7.  High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study.

Authors:  Shin-Chia Tsai; Shiow-Yunn Sheu; Li-Nien Chien; Hsin-Chien Lee; Eunice Jia-Shiow Yuan; Rey-Yue Yuan
Journal:  Br J Clin Pharmacol       Date:  2018-06-19       Impact factor: 4.335

8.  Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.

Authors:  Kristian Svendsen; Mollie Wood; Erika Olsson; Hedvig Nordeng
Journal:  Eur J Clin Pharmacol       Date:  2017-12-30       Impact factor: 2.953

Review 9.  Diabetes and the Stomach.

Authors:  Allen A Lee; William L Hasler
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

10.  Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.

Authors:  Antoine Pariente; Yohann Mansiaux; Ana Jarné; Francesco Salvo; Cécile Pageot; Julien Bezin; Andy Smith; Bernard Bégaud
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.